Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.33 |
| ▸ | MAPK7 | Q13164 | 2/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | LCAT | P04180 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994483 | 0.77 | PIK3CA (0.34) | CTSKKIT | |
| SCHEMBL2814467 | 0.73 | KIF11 (0.43) | HTR6HTR2B | |
| SCHEMBL28659226 | 0.63 | ACACB (0.50) | — | |
| SCHEMBL1991893 | 0.63 | CDK4 (0.36) | CHRM2CHRM1 | |
| SCHEMBL1994668 | 0.62 | CHRNB2 (0.42) | CHRM2CHRM1 | |
| SCHEMBL1990765 | 0.62 | NFE2L2 (0.37) | HTR6 | |
| SCHEMBL29120766 | 0.61 | FFAR1 (0.42) | — | |
| SCHEMBL19401230 | 0.61 | CA12 (0.42) | — | |
| SCHEMBL403812 | 0.61 | APP (0.50) | — | |
| SCHEMBL1991067 | 0.60 | BRD4 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | claimed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | claimed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | claimed |
| EP-2516440-B1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS | ABBVIE INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8524703-B2 | Bridgehead amine ring-fused indoles and indolines | ABBVIE INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2516440-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | Abbott Laboratories (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | US | disclosed |
| WO-2011075487-A1 | BRIDGEHEAD AMINE RING -FUSED INDOLES AND INDOLINES USEFUL TO TREAT NEURODEGENERATIVE AND NEUROPSYCHIATRY DISORDERS | ABBOTT LABORATORIES (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152248-A1 | BRIDGEHEAD AMINE RING-FUSED INDOLES AND INDOLINES | IDO2, IDO1, TPH2 | HTR6 26/4885AKR1C3 435/4885MAPK7 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.